Effects of long term octreotide on gall stone formation and gall bladder function.
نویسندگان
چکیده
1 Scott J. Lipoprotein(a). Thrombotic and atherogenic. BAf] 1991;303:663-4. 2 Fuller JH, Shipley MIJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-diseaserisk and impaired glucose tolerance: the Whitehall study. Lancet 1980;i: 1374-6. 3 Zimmet P. Non-insulin-dependent (type 2) diabetes mellitus: does it really exist? Diabetic Med 1989;6:728-35. 4 Schriewer H, Assmann G, Sandkamp M, Schulte H. The relationship of lipoprotein(a) (Lp(a)) to risk factors ofcoronary heart disease: initial results of the prospective epidemiological study on company emloyees in Westfalia. J Clin Chem Clin Biochem 1984;22:591-6. 5 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-2.
منابع مشابه
Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
BACKGROUND Octreotide treatment may be associated with gall stone development in up to 50% of patients with acromegaly. Two new sustained-release formulations of somatostatin analogue have been recently developed: lanreotide SR (Somatuline) and octreotide LAR (Sandostatin LAR). The incidence of gall-stone development in patients receiving these drugs has been shown to be less than 20%, but the ...
متن کاملEffect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
Octreotide therapy in acromegaly is associated with an increased prevalence of gall stones, which may be the result of an inhibition of gall bladder motility. Gall stone prevalence in untreated acromegalic patients relative to the general population is unknown, however, and the presence of gall stones and gall bladder motility in these patients and in acromegalic patients receiving octreotide w...
متن کاملPostprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.
Repeated daily injections of the somatostatin analogue, octreotide (SMS201-995, Sandostatin) are an effective treatment for acromegaly, but lead to gall stone formation in about 50% of cases during longterm treatment. This is probably because of impaired gall bladder contraction. This study examined whether the timing of intermittent injections in relation to meals, or alternatively, continuous...
متن کاملLyme disease facial palsy: differentiation from Bell's palsy.
there have been only isolated reports of gall stones occurring during octreotide treatment.' Gall bladder contraction and cholecystokinin secretion in response to food are almost abolished by its administration4 and may contribute to stone formation. The high incidence of gall stones might have been due to the higher doses of the drug which we used. None of our patients had symptoms from the ga...
متن کاملComposition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients. Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones. Chemical analysis of gall stones retrieved at cholecystectomy fr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- BMJ
دوره 304 6842 شماره
صفحات -
تاریخ انتشار 1992